Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective
oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-…

… The PRO analyses presented here show improvements in key lung cancer symptoms in both
… The overall burden of key lung cancer symptoms was low at baseline, with most patients in …

… patients were randomly assigned to gefitinib (gefitinib 250 mg orally once every day) or GCP
regimen (gefitinib … by concurrent gefitinib and pemetrexed maintenance). In the GCP group, …

… The current study examines the efficacy, safety, and tolerability of ASP8273 versus
erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR …

… For locally advanced lung cancer, there are no prospective studies that have … gefitinib
could improve the survival of patients with locally advanced EGFR-activating mutation lung …

… (†) Of 71 patients continuing on the gefitinib plus pemetrexed and carboplatin … , 47 patients
continue to receive both chemotherapy and gefitinib. Twenty-four patients have discontinued …

… Chinese patients with … -in, patients received savolitinib 600 or 800 mg plus gefitinib 250 mg
orally once daily, and dose-limiting toxicities were recorded. In the expansion phase, patients …

… In the present study, no differences in PFS were seen among the patients receiving gefitinib
alone or those receiving gefitinib plus olaparib, even though a trend towards longer PFS …

… In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly … gefitinib in patients with
treatment-naïve epidermal growth factor receptor mutation-positive non-small cell lung cancer…

… 20 of 114 patients did not receive any subsequent regimens after first-line gefitinib due to a
poor performance status, interstitial lung disease, exacerbation of co-morbidities, and patient …